# US 2023/0054375 A1 · Anti-cd47 antibody and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054375 A1
- Document ID: US20230054375A1
- Status: Published application
- Kind: A1
- Application number: 17/817,448
- Filed: 2022-08-04
- Published: 2023-02-23
- Earliest claimed: 2021-08-05
- Assignees: The UAB Research Foundation
- Applicants: The Uab Research Foundation
- Inventors: Xiaoguang Margaret LIU
- Web page: https://patentgrep.com/patent/US20230054375A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 35/00: Antineoplastic agents
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6809: {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6877: {the antibody being an immunoglobulin containing regions, domains or residues from different species}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 16/30: from tumour cells
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein is an antibody that selectively binds CD47 on tumor cells. Also disclosed is a method for treating cancer in a subject, comprising administering to the subject an effective amount of the antibody disclosed herein.

## Claims

### Claim 1

An antibody that selectively binds CD47 on tumor cells, comprising a variable heavy (VH) domain having CDR1, CDR2 and CDR3 sequences and a variable light (VL) domain having CDR1, CDR2 and CDR3 sequences, wherein
the CDR1 sequence of the VH domain comprises the amino acid sequence FTFNTYAMN (SEQ ID NO:5), the CDR2 sequence of the VH domain comprises the amino acid sequence WIARIRSKSNNYATYY (SEQ ID NO:6), the CDR3 sequence of the VH domain comprises the amino acid sequence RPAQGAMDY (SEQ ID NO:7), the CDR1 sequence of the VL comprises the amino acid sequence QRISNNLH (SEQ ID NO:8), the CDR2 sequence of the VL domain comprises the amino acid sequence LLIKYSSQSIS (SEQ ID NO:9), and the CDR3 sequence of the VL domain comprises the amino acid sequence QQSNAWPY (SEQ ID NO:10).

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the VH domain comprises the amino acid sequence SEQ ID NO:3.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the VH domain has at least 90% sequence identity to the amino acid sequence SEQ ID NO:3.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein the VL domain comprises the amino acid sequence SEQ ID NO:4.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein the VL domain has at least 90% sequence identity to the amino acid sequence SEQ ID NO:4.

### Claim 6 (depends on 1)

The antibody of claim 1, wherein the antibody is a monoclonal antibody.

### Claim 7 (depends on 1)

The antibody of claim 1, wherein the antibody is humanized.

### Claim 8 (depends on 1)

The antibody of claim 1, wherein the antibody is a chimeric antibody.

### Claim 9 (depends on 1)

The antibody of claim 1, wherein the antibody is conjugated to a cytotoxin to form an antibody-drug conjugate.

### Claim 10 (depends on 9)

The antibody of claim 9, wherein the cytotoxin is selected from the group consisting of an auristatin, a calicheamicin, a maytansinoid, or a tubulysin.

### Claim 11 (depends on 9)

The antibody of claim 9, wherein the cytotoxin is monomethylauristatin E, monomethylauristatin F, calicheamicin γ, mertansine, tubulysin T3, or tubulysin T4.

### Claim 12 (depends on 1)

A method for treating cancer in a subject, comprising administering to the subject an effective amount of the antibody of claim 1.